Evidence map›Paper›PMID 35905129›Full record

ArticlePloS one2022

Hospitalized patients dying with SARS-CoV-2 infection-An analysis of patient characteristics and management in ICU and general ward of the LEOSS registry.

Claudia Raichle, Stefan Borgmann, Claudia Bausewein, Siegbert Rieg, Carolin E M Jakob, Steffen T Simon, Lukas Tometten, Jörg Janne Vehreschild, Charlotte Leisse, Johanna Erber and 13 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 13 institutions in 1 country.

Claudia RaichleDepartment of Geriatric and Palliative Medicine, Tropenklinik Paul-Lechler-Krankenhaus, Tübingen, Germany.ORCID 0000-0003-4452-0369
Stefan BorgmannDepartment of Infectious Diseases and Infection Control, Ingolstadt Hospital, Ingolstadt, Germany.
Claudia BauseweinDepartment of Palliative Medicine, LMU Hospital, München, Germany.
Siegbert RiegDivision of Infectious Diseases, Department of Medicine II, Medical Centre-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Carolin E M JakobDepartment I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Steffen T SimonDepartment of Palliative Medicine, Faculty of Medicine, University of Cologne, Cologne, Germany.
Lukas TomettenDepartment I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Jörg Janne VehreschildDepartment I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Charlotte LeisseDepartment I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.
Johanna ErberDepartment of Internal Medicine II, University Hospital rechts der Isar, Technical University of Munich, Munich, Germany.
Melanie StecherDepartment I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0002-3460-1299
Berenike PauliDepartment of Palliative Medicine, Faculty of Medicine, University of Cologne, Cologne, Germany.
Maria Madeleine RüthrichDepartment of Internal Medicine II, Hematology and Medical Oncology, University Hospital Jena, Jena, Germany.
Lisa PilgramCenter for Internal Medicine, Medical Department 2, Hematology/Oncology and Infectious Diseases, University Hospital of Frankfurt, Frankfurt, Germany.ORCID 0000-0002-1020-0650
Frank HansesEmergency Department, University Hospital Regensburg, Regensburg, Germany.
Nora IsbernerDepartment of Internal Medicine II, Division of Infectious Diseases, University Hospital Würzburg, Würzburg, Germany.
Martin HowerDepartment of Internal Medicine, Klinikum Dortmund, Dortmund, Germany.ORCID 0000-0001-5967-5238
Christian DegenhardtDepartment of Pharmacy, Städtisches Klinikum, Karlsruhe, Germany.
Bernd HertensteinKlinikum Bremen-Mitte, Bremen, Germany.
Maria J G T VehreschildDepartment of Internal Medicine 2, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
Christoph RömmeleDepartment of Internal Medicine III-Gastroenterology and Infectious Diseases, University Hospital Augsburg, Augsburg, Germany.
Norma JungDepartment I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0002-5740-0772
LEOSS Study Group
University of Cologne · DEGoethe University Frankfurt · DEJena University Hospital · DEKlinikum Bremen-Mitte · DEKlinikum Dortmund · DEKlinikum Ingolstadt · DELMU Klinikum · DEStädtisches Klinikum Karlsruhe · DETUM Klinikum · DEUniversitätsklinikum Würzburg · DEUniversity Hospital Augsburg · DEUniversity Hospital Regensburg · DEUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 is a severe disease with a high need for intensive care treatment and a high mortality rate in hospitalized patients. The objective of this study was to describe and compare the clinical characteristics and the management of patients dying with SARS-CoV-2 infection in the acute medical and intensive care setting.

methodsDescriptive analysis of dying patients enrolled in the Lean European Open Survey on SARS-CoV-2 Infected Patients (LEOSS), a non-interventional cohort study, between March 18 and November 18, 2020. Symptoms, comorbidities and management of patients, including palliative care involvement, were compared between general ward and intensive care unit (ICU) by univariate analysis.

results580/4310 (13%) SARS-CoV-2 infected patients died. Among 580 patients 67% were treated on ICU and 33% on a general ward. The spectrum of comorbidities and symptoms was broad with more comorbidities (≥ four comorbidities: 52% versus 25%) and a higher age distribution (>65 years: 98% versus 70%) in patients on the general ward. 69% of patients were in an at least complicated phase at diagnosis of the SARS-CoV-2 infection with a higher proportion of patients in a critical phase or dying the day of diagnosis treated on ICU (36% versus 11%). While most patients admitted to ICU came from home (71%), patients treated on the general ward came likewise from home and nursing home (44% respectively) and were more frequently on palliative care before admission (29% versus 7%). A palliative care team was involved in dying patients in 15%. Personal contacts were limited but more often documented in patients treated on ICU (68% versus 47%).

conclusionPatients dying with SARS-CoV-2 infection suffer from high symptom burden and often deteriorate early with a demand for ICU treatment. Therefor a demand for palliative care expertise with early involvement seems to exist.

Indexed as

COVID-19AgedCohort StudiesHumansIntensive Care UnitsPatients' RoomsRegistriesSARS-CoV-2

Identifiers

PMID35905129
PMCPMC9337665
OpenAlexW4288709988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.